Journal of Taibah University Medical Sciences

Chitosan and nanochitosan haemostatic agents attenuate haemorrhagic coagulopathy and fibrinolysis: a rabbit study

Journal of Taibah University Medical Sciences

Date: 19-10-2026

Volume: 21 · Issue: 5 · Pages: 1260–1273

Show more

Original Article

Chitosan and nanochitosan haemostatic agents attenuate haemorrhagic coagulopathy and fibrinolysis: a rabbit study

Show more

Abstract

Background

Uncontrolled haemorrhage is the leading cause of potentially survivable death in combat casualties.

Aim

To compare the effects of a chitosan-based and a nanochitosan-based haemostatic agent with a reference agent on coagulation, fibrinolysis, platelets and angiogenic growth factors in an experimental haemorrhage model.

Methods

Thirty adult rabbits (2.1–2.3 kg) were randomly allocated to five groups (n = 6): intact, untreated haemorrhage (control), reference agent, chitosan and nanochitosan. Blood loss, bleeding time, prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), international normalised ratio (INR), fibrinogen, D-dimer, platelet count, vascular endothelial growth factor (VEGF) and transforming growth factor-β (TGF-β) were measured 1, 3, 12, 24 and 72 h after injury.

Results

In untreated animals, blood loss was 8.27–8.50 mL and bleeding time 19.8–23.6 min. Haemorrhage prolonged PT (12.83 to 16.55 s) and APTT (36.83 to 64.5 s), increased D-dimer more than fivefold (0.25 to 1.33 µg/mL) and reduced platelets (333.3 to 237.2 × 103/µL) by 72 h. All agents attenuated these changes, most markedly nanochitosan: PT was 9.4% and 11.0% shorter than in controls at 1 and 72 h, APTT 12.2% and 12.7% shorter, D-dimer 2.2-fold lower (0.47 and 0.60 vs. 1.03 and 1.33 µg/mL) and platelets higher (278.5 and 280.0 vs. 249.0 and 237.2 × 103/µL). Haemorrhage increased VEGF (97.5 to 189.7 ng/mL) and TGF-β (72.7 to 267.5 pg/mL); the rise was smallest with nanochitosan (152.8 ng/mL and 238.5 pg/mL at 72 h).

Conclusion

In this rabbit model, nanochitosan attenuated haemorrhage-associated coagulopathy, hyperfibrinolysis and thrombocytopenia more effectively than conventional chitosan or the reference agent. Confirmation of local haemostatic efficacy and thrombotic safety in standardised large-animal models is required before clinical use.

Authors and affiliations

Alisher T. Tukhtapulatov
Military Medical Institute, University of Military Security and Defense of the Republic of Uzbekistan, Tashkent, Republic of Uzbekistan
Corresponding author
nagaeva.gulnora@mail.ru

Z.A. Pulatova
Military Medical Institute, University of Military Security and Defense of the Republic of Uzbekistan, Tashkent, Republic of Uzbekistan

R.Y. Milusheva
Military Medical Institute, University of Military Security and Defense of the Republic of Uzbekistan, Tashkent, Republic of Uzbekistan

V.N. Raxmanova
Military Medical Institute, University of Military Security and Defense of the Republic of Uzbekistan, Tashkent, Republic of Uzbekistan

D.B. Axmedova
Military Medical Institute, University of Military Security and Defense of the Republic of Uzbekistan, Tashkent, Republic of Uzbekistan

F.X. Mirdjalilov
Military Medical Institute, University of Military Security and Defense of the Republic of Uzbekistan, Tashkent, Republic of Uzbekistan

Z.R. Xasanov
Military Medical Institute, University of Military Security and Defense of the Republic of Uzbekistan, Tashkent, Republic of Uzbekistan

Keywords

Blood Coagulation; Chitosan; Hemorrhage; Hemostatics; Nanoparticles; Wounds and Injuries

Full article

The PDF viewer is unavailable. Download the full article PDF.

How to cite

Tukhtapulatov A. T., Pulatova Z. A., Milusheva R. Y., Raxmanova V. N., Axmedova D. B., Mirdjalilov F. X., Xasanov Z. R. (2026). Chitosan and nanochitosan haemostatic agents attenuate haemorrhagic coagulopathy and fibrinolysis: a rabbit study. Journal of Taibah University Medical Sciences, 21(5), 1260–1273. DOI: 10.1016/j.jtumed.2026.10.19.